Joshua D. Rosenblat, MD, MSc, FRCPC

  • 7Articles
  • 62.7KReads
  • 2017–2025Active
  • 29Collaborators
  • 484Citations

About

Joshua D. Rosenblat, MD, MSc, FRCPC, is affiliated with the Brain and Cognition Discovery Foundation and the Department of Pharmacology and Toxicology at the University of Toronto. His publications, spanning from 2017 to 2025, focus on clinical topics including major depressive disorder, bipolar disorder, psychiatry, and suicidality. His work covers areas such as ketamine and esketamine treatments, deprescribing practices, pharmacogenomic testing, and factors influencing treatment decisions in mood disorders. He has frequently collaborated with Roger S. McIntyre and other colleagues.

Publications

JCP
Global Population-Based Study on the Association Between Ketamine and Esketamine with Suicidality Using WHO VigiBase
Original Research

Global Population-Based Study on the Association Between Ketamine and Esketamine with Suicidality Using WHO VigiBase

July 7, 2025

The results do not provide causal evidence of worsening suicidality in persons receiving esketamine/ketamine; mixed results of increased and decreased risk of suicidality were reported with both agents.
, , , et al
JCP
What Is Meant by the Term “Deprescribing,” and Does It Belong in Our Lexicon?
ASCP Corner

What Is Meant by the Term “Deprescribing,” and Does It Belong in Our Lexicon?

June 2, 2025

The authors encourage the field to destigmatize the term “deprescribing” from its misappropriated usage, explicate its accurate definition, and reclaim its purposeful meaning.
, , , et al
JCP
Correction

Correction: Oral Ketamine for Depression

April 22, 2020

, , , et al
JCP
Letter to the Editor

Drs Rosenblat and McIntyre Reply

January 28, 2020

 Rosenblat and McIntyre reply to the letter "Sublingual Ketamine: An Option for Increasing Accessibility of Ketamine Treatments for Depression?" by Swainson and Khullar.
,
JCP
Review Article

Oral Ketamine for Depression

April 16, 2019

Intravenous ketamine has rapid and robust antidepressant effects. Read this systematic review to learn if oral ketamine also has efficacy and tolerability in depressed individuals.
, , , et al
PCC
Article

Factors that Impact Treatment Decisions

November 1, 2018

What patient-reported factors influence medication treatment decisions among individuals with bipolar and unipolar depression? The authors of this article conducted a survey to answer this question. Their findings may...
, , , et al
JCP
Review Article

Pharmacogenomic Testing and MDD Outcomes

June 28, 2017

In theory, pharmacogenomic testing in patients with depression can improve clinical outcomes by guiding antidepressant selection and dosing. This review looks at the current evidence to evaluate the clinical...
, ,

Physicians Postgraduate Press, Inc. (PPP) makes no warranties about the accuracy or completeness of any information published in The Journal of Clinical Psychiatry or other PPP materials, and disclaims liability for any use or non-use of that information. Clinicians should not rely solely on these materials and should exercise their own professional judgment when making patient care decisions on an individualized basis.

Learn More About Psychedelics in Psychiatry

Explore the Collection
Neural network illustration symbolizing psychedelic research advancements

Subscribe to read
more articles

Subscribe